ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet2008245-54ometendo-6879Research ArticleСтатьиArticlesНовости мировой медициныWorld endocrinology newsБерковскаяМ АBerkovskayaM A-ФГУ "Эндокринологический научный центр" РосмедтехнологийEndocrinology Research Centre, Moscow20081506200852№2 (2008)4554Copyright © Берковская М.А., 20082008Берковская М.А.Berkovskaya M.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/6879

Роль интерлейкина-6 в развитии инсулинорезистентности, распределении жировой ткани и энергетическом балансе. Гиперурикемия и риск сахарного диабета 2 типа в китайской популяции. Нарушения обмена глюкозы и риск рака ротовой полости. Длительность лактации ассоциирована со снижением частоты метаболического синдрома. Недостаточность витамина D и риск развития сердечно-сосудистых заболеваний. Пролактин, синтезируемый адипоцитами: регуляция секреции и предполагаемые функции. Более выраженная абсолютная польза Фенофибрата у пациентов в исследовании FIELD, имевших атерогенную дислипидемию и метаболический синдром (по материалам презентации профессора Энтони Кича: Признаки метаболического синдрома позволяют выявить категорию лиц с СД 2 типа и высоким риском сердечно-сосудистых осложнений, которые получат наибольшую абсолютную пользу от терапии фенофибратом).

The role of interleukin-6 in insulin resistance, body fat distribution and energy balance Disorders of glucose metabolism and risk of oral cancer. Duration of lactation is associated with lower prevalence of the metabolic syndrome in midlife--SWAN, the study of women's health across the nation. Vitamin D deficiency and risk of cardiovascular disease. Adypocyte prolactin: regulation of release and putative functions.

ReferencesObesity reviews (2008) 9, 20-29Obesity reviews (2008) 9, 20-29Hoene M., Weigert C. The role of interleukin-6 in insulin resistence, body fat distribution and energy balance. Obesity reviews 2008;9:20-29.Hoene M., Weigert C. The role of interleukin-6 in insulin resistence, body fat distribution and energy balance. Obesity reviews 2008;9:20-29.Chien KL, Chen MF, Hsu HC, Chang WT, Su TC, Lee YT, Hu FB. Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin Chem. 2008 Feb;54(2):310-6.Chien KL, Chen MF, Hsu HC, Chang WT, Su TC, Lee YT, Hu FB. Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin Chem. 2008 Feb;54(2):310-6.Suba Z, Ujpa l M. Disorders of glucose metabolism and risk of oral cancer. Fogorv Sz. 2007 Oct;100(5):250-7, 243-9Suba Z, Ujpa l M. Disorders of glucose metabolism and risk of oral cancer. Fogorv Sz. 2007 Oct;100(5):250-7, 243-9Ram KT, Bobby P, Hailpern SM, Lo JC, Schocken M, Skurnick J, Santoro N. Duration of lactation is associated with lower prevalence of the metabolic syndrome in midlife--SWAN, the study of women's health across the nation. Am J Obstet Gynecol. 2008;198(3):268.e1-6.Ram KT, Bobby P, Hailpern SM, Lo JC, Schocken M, Skurnick J, Santoro N. Duration of lactation is associated with lower prevalence of the metabolic syndrome in midlife--SWAN, the study of women's health across the nation. Am J Obstet Gynecol. 2008;198(3):268.e1-6.Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503-11.Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503-11.Brandebourg T., Hugo E., Ben-Jonathan N. Adypocyte prolactin: regulation of release and putative functions. Diabetes, Obesity and Metabolism, 9, 2007, 464-476Brandebourg T., Hugo E., Ben-Jonathan N. Adypocyte prolactin: regulation of release and putative functions. Diabetes, Obesity and Metabolism, 9, 2007, 464-476Scott R, d’Emden M, Best J, et al; on behalf of the FIELD Investigators. Features of metabolic syndrome identify individuals with type 2 diabetes melli- tus at high risk for cardiovascular events and greater absolute benefits of fenofibrate. Circulation 2007;116(Suppl II):838 (abstract 3691).Scott R, d’Emden M, Best J, et al; on behalf of the FIELD Investigators. Features of metabolic syndrome identify individuals with type 2 diabetes melli- tus at high risk for cardiovascular events and greater absolute benefits of fenofibrate. Circulation 2007;116(Suppl II):838 (abstract 3691).Burgess D, Hunt D, Li LP, et al; on behalf of the FIELD Investigators. Effects of fenofibrate on silent myocardial infarction, hospitalization for acute coronary syn- dromes and amputation in type 2 diabetes: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Circulation 2007;116(Suppl II):838 (abstract 3693).Burgess D, Hunt D, Li LP, et al; on behalf of the FIELD Investigators. Effects of fenofibrate on silent myocardial infarction, hospitalization for acute coronary syn- dromes and amputation in type 2 diabetes: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Circulation 2007;116(Suppl II):838 (abstract 3693).

The authors declare that there are no conflicts of interest present.